Global (United States, European Union and China) Erythropoietin Drugs

Erythropoietin Drugs Comprehensive Study by Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), Application (Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis), Others (Neural Disease and Wound healing)), Drug Class (Biologics, Biosimilars), End User () Players and Region - Global Market Outlook to 2026

Erythropoietin Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Erythropoietin Drugs Market Scope
The global erythropoietin drugs market size is expected to witness a growth in the forecast period due to an increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV. Erythropoietin drugs are also known as hematopoietic. It is a glycoprotein hormone that controls erythropoiesis or the production of RBC. To curb the rising incidence of anemia, the demand for Erythropoietin (EPO) drugs is expected to increase over the coming years.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Erythropoietin Drugs market throughout the predicted period.

Hoffmann-La Roche (Switzerland), Johnson & Johnson (United States), Amgen (United States), Kyowa Hakko Kirin (Japan), Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India), Celltrion, Inc. (South Korea), Hospira (United States) and Dahua Pharmaceutical (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are LG Life Sciences Ltd. (Korea), 3SBio (China), Boehringer Ingelheim (United States) and BIOSIDUS (Argentina).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Erythropoietin Drugs market by Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others), by Application (Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis) and Others (Neural Disease and Wound healing)) and Region with country level break-up.

On the basis of geography, the market of Erythropoietin Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In May 2018, The U.S. Food and Drug Administration approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.


Market Trend
  • Growing Commercialization for Erythropoietin Biosimilars

Market Drivers
  • Increasing Number Cases Including Cancer,HIV, Kidney Disease and Anaemia
  • Rising Awareness about the Benefits of EPO Therapeutics

Opportunities
  • Commercialization of Darbepoetin Alfa Biosimilar
  • Achieving Economies of Scale Across Developed Region with Biosimilar Version of EPO

Restraints
  • High Cost of the Drugs
  • Adverse Amount of Side Effects

Challenges
  • Longer Duration of Treatments


Key Target Audience
Pharmaceutical companies, Research and Development (R&D) Companies, Government and Independent Research Laboratories, Contract Research Organizations (CROs), Medical Research Laboratories and Academic Medical Institutes and Universities

Report Objectives / Segmentation Covered

By Type
  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others
By Application
  • Anemia (Cancer and HIV treatment)
  • Kidney Disorders (ESRD and Dialysis)
  • Others (Neural Disease and Wound healing)
By Drug Class
  • Biologics
  • Biosimilars

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number Cases Including Cancer,HIV, Kidney Disease and Anaemia
      • 3.2.2. Rising Awareness about the Benefits of EPO Therapeutics
    • 3.3. Market Challenges
      • 3.3.1. Longer Duration of Treatments
    • 3.4. Market Trends
      • 3.4.1. Growing Commercialization for Erythropoietin Biosimilars
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Erythropoietin Drugs, by Type, Application, Drug Class, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Erythropoietin Drugs (Value)
      • 5.2.1. Global Erythropoietin Drugs by: Type (Value)
        • 5.2.1.1. Epoetin-alfa
        • 5.2.1.2. Epoetin-beta
        • 5.2.1.3. Darbepoetin-alfa
        • 5.2.1.4. Others
      • 5.2.2. Global Erythropoietin Drugs by: Application (Value)
        • 5.2.2.1. Anemia (Cancer and HIV treatment)
        • 5.2.2.2. Kidney Disorders (ESRD and Dialysis)
        • 5.2.2.3. Others (Neural Disease and Wound healing)
      • 5.2.3. Global Erythropoietin Drugs by: Drug Class (Value)
        • 5.2.3.1. Biologics
        • 5.2.3.2. Biosimilars
      • 5.2.4. Global Erythropoietin Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Erythropoietin Drugs (Price)
      • 5.3.1. Global Erythropoietin Drugs by: Type (Price)
  • 6. Erythropoietin Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hoffmann-La Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Kyowa Hakko Kirin (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Intas Pharmaceuticals (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biocon (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Emcure Pharmaceuticals (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Celltrion, Inc. (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hospira (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Dahua Pharmaceutical (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Erythropoietin Drugs Sale, by Type, Application, Drug Class, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Erythropoietin Drugs (Value)
      • 7.2.1. Global Erythropoietin Drugs by: Type (Value)
        • 7.2.1.1. Epoetin-alfa
        • 7.2.1.2. Epoetin-beta
        • 7.2.1.3. Darbepoetin-alfa
        • 7.2.1.4. Others
      • 7.2.2. Global Erythropoietin Drugs by: Application (Value)
        • 7.2.2.1. Anemia (Cancer and HIV treatment)
        • 7.2.2.2. Kidney Disorders (ESRD and Dialysis)
        • 7.2.2.3. Others (Neural Disease and Wound healing)
      • 7.2.3. Global Erythropoietin Drugs by: Drug Class (Value)
        • 7.2.3.1. Biologics
        • 7.2.3.2. Biosimilars
      • 7.2.4. Global Erythropoietin Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Erythropoietin Drugs (Price)
      • 7.3.1. Global Erythropoietin Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Erythropoietin Drugs: by Type(USD Million)
  • Table 2. Erythropoietin Drugs Epoetin-alfa , by Region USD Million (2015-2020)
  • Table 3. Erythropoietin Drugs Epoetin-beta , by Region USD Million (2015-2020)
  • Table 4. Erythropoietin Drugs Darbepoetin-alfa , by Region USD Million (2015-2020)
  • Table 5. Erythropoietin Drugs Others , by Region USD Million (2015-2020)
  • Table 6. Erythropoietin Drugs: by Application(USD Million)
  • Table 7. Erythropoietin Drugs Anemia (Cancer and HIV treatment) , by Region USD Million (2015-2020)
  • Table 8. Erythropoietin Drugs Kidney Disorders (ESRD and Dialysis) , by Region USD Million (2015-2020)
  • Table 9. Erythropoietin Drugs Others (Neural Disease and Wound healing) , by Region USD Million (2015-2020)
  • Table 10. Erythropoietin Drugs: by Drug Class(USD Million)
  • Table 11. Erythropoietin Drugs Biologics , by Region USD Million (2015-2020)
  • Table 12. Erythropoietin Drugs Biosimilars , by Region USD Million (2015-2020)
  • Table 13. South America Erythropoietin Drugs, by Country USD Million (2015-2020)
  • Table 14. South America Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 15. South America Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 16. South America Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 17. Brazil Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 18. Brazil Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 19. Brazil Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 20. Argentina Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 21. Argentina Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 22. Argentina Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 23. Rest of South America Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 26. Asia Pacific Erythropoietin Drugs, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 30. China Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 31. China Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 32. China Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 33. Japan Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 34. Japan Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 35. Japan Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 36. India Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 37. India Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 38. India Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 39. South Korea Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 40. South Korea Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 41. South Korea Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 42. Taiwan Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 43. Taiwan Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 44. Taiwan Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 45. Australia Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 46. Australia Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 47. Australia Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 51. Europe Erythropoietin Drugs, by Country USD Million (2015-2020)
  • Table 52. Europe Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 53. Europe Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 54. Europe Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 55. Germany Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 56. Germany Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 57. Germany Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 58. France Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 59. France Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 60. France Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 61. Italy Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 62. Italy Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 63. Italy Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 64. United Kingdom Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 67. Netherlands Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 68. Netherlands Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 69. Netherlands Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 70. Rest of Europe Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 73. MEA Erythropoietin Drugs, by Country USD Million (2015-2020)
  • Table 74. MEA Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 75. MEA Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 76. MEA Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 77. Middle East Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 78. Middle East Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 79. Middle East Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 80. Africa Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 81. Africa Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 82. Africa Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 83. North America Erythropoietin Drugs, by Country USD Million (2015-2020)
  • Table 84. North America Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 85. North America Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 86. North America Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 87. United States Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 88. United States Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 89. United States Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 90. Canada Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 91. Canada Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 92. Canada Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 93. Mexico Erythropoietin Drugs, by Type USD Million (2015-2020)
  • Table 94. Mexico Erythropoietin Drugs, by Application USD Million (2015-2020)
  • Table 95. Mexico Erythropoietin Drugs, by Drug Class USD Million (2015-2020)
  • Table 96. Erythropoietin Drugs: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Erythropoietin Drugs: by Type(USD Million)
  • Table 109. Erythropoietin Drugs Epoetin-alfa , by Region USD Million (2021-2026)
  • Table 110. Erythropoietin Drugs Epoetin-beta , by Region USD Million (2021-2026)
  • Table 111. Erythropoietin Drugs Darbepoetin-alfa , by Region USD Million (2021-2026)
  • Table 112. Erythropoietin Drugs Others , by Region USD Million (2021-2026)
  • Table 113. Erythropoietin Drugs: by Application(USD Million)
  • Table 114. Erythropoietin Drugs Anemia (Cancer and HIV treatment) , by Region USD Million (2021-2026)
  • Table 115. Erythropoietin Drugs Kidney Disorders (ESRD and Dialysis) , by Region USD Million (2021-2026)
  • Table 116. Erythropoietin Drugs Others (Neural Disease and Wound healing) , by Region USD Million (2021-2026)
  • Table 117. Erythropoietin Drugs: by Drug Class(USD Million)
  • Table 118. Erythropoietin Drugs Biologics , by Region USD Million (2021-2026)
  • Table 119. Erythropoietin Drugs Biosimilars , by Region USD Million (2021-2026)
  • Table 120. South America Erythropoietin Drugs, by Country USD Million (2021-2026)
  • Table 121. South America Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 122. South America Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 123. South America Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 124. Brazil Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 125. Brazil Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 126. Brazil Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 127. Argentina Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 128. Argentina Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 129. Argentina Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 130. Rest of South America Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 131. Rest of South America Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 132. Rest of South America Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 133. Asia Pacific Erythropoietin Drugs, by Country USD Million (2021-2026)
  • Table 134. Asia Pacific Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 135. Asia Pacific Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 136. Asia Pacific Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 137. China Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 138. China Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 139. China Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 140. Japan Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 141. Japan Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 142. Japan Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 143. India Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 144. India Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 145. India Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 146. South Korea Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 147. South Korea Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 148. South Korea Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 149. Taiwan Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 150. Taiwan Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 151. Taiwan Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 152. Australia Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 153. Australia Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 154. Australia Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 158. Europe Erythropoietin Drugs, by Country USD Million (2021-2026)
  • Table 159. Europe Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 160. Europe Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 161. Europe Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 162. Germany Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 163. Germany Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 164. Germany Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 165. France Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 166. France Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 167. France Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 168. Italy Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 169. Italy Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 170. Italy Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 171. United Kingdom Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 172. United Kingdom Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 173. United Kingdom Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 174. Netherlands Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 175. Netherlands Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 176. Netherlands Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 177. Rest of Europe Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 178. Rest of Europe Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 179. Rest of Europe Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 180. MEA Erythropoietin Drugs, by Country USD Million (2021-2026)
  • Table 181. MEA Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 182. MEA Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 183. MEA Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 184. Middle East Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 185. Middle East Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 186. Middle East Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 187. Africa Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 188. Africa Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 189. Africa Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 190. North America Erythropoietin Drugs, by Country USD Million (2021-2026)
  • Table 191. North America Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 192. North America Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 193. North America Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 194. United States Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 195. United States Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 196. United States Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 197. Canada Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 198. Canada Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 199. Canada Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 200. Mexico Erythropoietin Drugs, by Type USD Million (2021-2026)
  • Table 201. Mexico Erythropoietin Drugs, by Application USD Million (2021-2026)
  • Table 202. Mexico Erythropoietin Drugs, by Drug Class USD Million (2021-2026)
  • Table 203. Erythropoietin Drugs: by Type(USD/Units)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Erythropoietin Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Erythropoietin Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Erythropoietin Drugs: by Drug Class USD Million (2015-2020)
  • Figure 7. South America Erythropoietin Drugs Share (%), by Country
  • Figure 8. Asia Pacific Erythropoietin Drugs Share (%), by Country
  • Figure 9. Europe Erythropoietin Drugs Share (%), by Country
  • Figure 10. MEA Erythropoietin Drugs Share (%), by Country
  • Figure 11. North America Erythropoietin Drugs Share (%), by Country
  • Figure 12. Global Erythropoietin Drugs: by Type USD/Units (2015-2020)
  • Figure 13. Global Erythropoietin Drugs share by Players 2020 (%)
  • Figure 14. Global Erythropoietin Drugs share by Players (Top 3) 2020(%)
  • Figure 15. Global Erythropoietin Drugs share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2020
  • Figure 19. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 20. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 21. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 22. Amgen (United States) Revenue: by Geography 2020
  • Figure 23. Kyowa Hakko Kirin (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Kyowa Hakko Kirin (Japan) Revenue: by Geography 2020
  • Figure 25. Intas Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 26. Intas Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 27. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 29. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 30. Biocon (India) Revenue: by Geography 2020
  • Figure 31. Emcure Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 32. Emcure Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 33. Celltrion, Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 34. Celltrion, Inc. (South Korea) Revenue: by Geography 2020
  • Figure 35. Hospira (United States) Revenue, Net Income and Gross profit
  • Figure 36. Hospira (United States) Revenue: by Geography 2020
  • Figure 37. Dahua Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 38. Dahua Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 39. Global Erythropoietin Drugs: by Type USD Million (2021-2026)
  • Figure 40. Global Erythropoietin Drugs: by Application USD Million (2021-2026)
  • Figure 41. Global Erythropoietin Drugs: by Drug Class USD Million (2021-2026)
  • Figure 42. South America Erythropoietin Drugs Share (%), by Country
  • Figure 43. Asia Pacific Erythropoietin Drugs Share (%), by Country
  • Figure 44. Europe Erythropoietin Drugs Share (%), by Country
  • Figure 45. MEA Erythropoietin Drugs Share (%), by Country
  • Figure 46. North America Erythropoietin Drugs Share (%), by Country
  • Figure 47. Global Erythropoietin Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Hoffmann-La Roche (Switzerland)
  • Johnson & Johnson (United States)
  • Amgen (United States)
  • Kyowa Hakko Kirin (Japan)
  • Intas Pharmaceuticals (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Biocon (India)
  • Emcure Pharmaceuticals (India)
  • Celltrion, Inc. (South Korea)
  • Hospira (United States)
  • Dahua Pharmaceutical (China)
Additional players considered in the study are as follows:
LG Life Sciences Ltd. (Korea) , 3SBio (China) , Boehringer Ingelheim (United States) , BIOSIDUS (Argentina)
Select User Access Type

Key Highlights of Report


Jan 2022 243 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Erythropoietin Drugs Quantitative research analysis
Global (United States, European Union and China) Erythropoietin Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Erythropoietin Drugs study can be customized to meet your requirements. The market size breakdown by type [Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others], by end use application [Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis) and Others (Neural Disease and Wound healing)].
The Erythropoietin Drugs Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Erythropoietin Drugs market is expected to see growth rate of %.

Know More About Global (United States, European Union and China) Erythropoietin Drugs Report?

Have a Query? Click Here

Other Related Reports

Diaper Rash Cream Comprehensive Study by Type (Zinc Oxide-based, Zinc Oxide Free), Application (Hospitals and Clinics, Personal Care, Other), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy...
$ 3650
Pig Vaccine Comprehensive Study by Application (Veterinary Hospitals, Hog Production Farms), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjuga...
$ 3750
Intravenous Immunoglobulin (IVIg) Comprehensive Study by Type (Gammagard S/D, Gammagard Liquid, Gamunex, IGIVnex, Privigen, Others), Application (Neurology, Haematology, Immunology, Dermatology, Othe...
$ 3450
Fondaparinux Comprehensive Study by Type (Branded, Generic), Application (Home Care Settings, Hip/Knee Replacement, Cardiovascular, Abdominal Surgery, Other), Sales Channel (Third-Party Website, Manu...
$ 3650
Oxcarbazepine Drug Comprehensive Study by Type (Oxcarbazepine Tablet, Oral suspension), Application (Adult, Pediatric), Dosage (150 mg, 300 mg, 600 mg) Players and Region - Global Market Outlook to 2...
$ 3500
Traditional Chinese Medicine Comprehensive Study by Type (Chinese Herbal Medicine, Acupuncture, Tai Chi, Cupping, Moxibustion, Others), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, O...
$ 3800